Anti–tumor necrosis factor-alfa and psoriasis: New insights on keratinocyte differentiation markers - 13/02/13
Francesca Prignano, MD, PhD, Division of Clinical, Preventive and Oncology Dermatology, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy; Alice Gualerzi, PhD, Dipartimento di Morfologia Umana e Scienze Biomediche – Città Studi, Università degli Studi di Milano, Milan, Italy; Elena Donetti, PhD, Dipartimento di Morfologia Umana e Scienze Biomediche – Città Studi, Università degli Studi di Milano, Milan, Italy; Federica Ricceri, MD, Division of Clinical, Preventive and Oncology Dermatology, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy; Lara Tripo, MD, Division of Clinical, Preventive and Oncology Dermatology, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy; Leonardo Pescitelli, MD, Division of Clinical, Preventive and Oncology Dermatology, Department of Critical Care Medicine and Surgery, University of Florence, Florence, Italy; Marzia Bedoni, PhD, Polo Tecnologico, Fondazione Don Carlo Gnocchi, Milan, Italy
Le texte complet de cet article est disponible en PDF.| Commercial support: None identified. |
Vol 68 - N° 4S1
P. AB193 - avril 2013 Retour au numéro
Article précédent
- An evaluation of the effect of topical tofacitinib (CP-690, 550) on pruritus and patient satisfaction with study medication in a phase IIA trial for plaque psoriasis
- Anti–tumor necrosis factor-alfa–induced drug eruptions: One patient, more than a pattern
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?